151. An open trial of transdermal nicotine replacement therapy for smoking cessation among alcohol- and drug-dependent inpatients.
- Author
-
Saxon AJ, McGuffin R, and Walker RD
- Subjects
- Administration, Cutaneous, Adult, Female, Humans, Male, Nicotine administration & dosage, Nicotine adverse effects, Nicotinic Agonists administration & dosage, Nicotinic Agonists adverse effects, Smoking psychology, Smoking Cessation psychology, Alcoholism complications, Alcoholism psychology, Nicotine therapeutic use, Nicotinic Agonists therapeutic use, Smoking Cessation methods, Substance-Related Disorders complications, Substance-Related Disorders psychology
- Abstract
An open trial of transdermal nicotine replacement for smoking cessation was conducted. Over a 7-month period, all patients admitted to the inpatient alcohol and drug treatment unit of the Seattle Veterans Affairs Medical Center, (n = 207) were offered the opportunity to participate in an open trial of transdermal nicotine replacement for smoking cessation. Forty-nine (23.7%) elected to attempt cessation with transdermal nicotine during their inpatient treatment episodes. These subjects received no psychosocial treatments directed specifically at smoking cessation. They smoked a mean of 28.5 (SD = 16.4) cigarettes per day and obtained a mean score of 8.3 (SD = 1.9) on the Fagerstrom Test for Nicotine Dependence. Subjects remained on transdermal nicotine an average of 18.8 (SD = 8.2) days with desire to resume smoking the major reason for discontinuation. Seven subjects (14.3%) self-reported tobacco abstinence at 21 days, and 5 (10.2%) self-reported abstinence as outpatients at 6 weeks. These results show that a substantial proportion of alcohol- and drug-dependent patients entering inpatient treatment are willing to attempt alcohol and illicit drug cessation and tobacco cessation simultaneously and that transdermal nicotine holds promise as a treatment modality in this population.
- Published
- 1997
- Full Text
- View/download PDF